iBio, Inc. (IBIO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
iBio, Inc. (IBIO) Reports Q1 Loss
iBio, Inc. (IBIO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.46 per share a year ago.
iBio, Inc. (IBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has iBio, Inc. ever had a stock split?
iBio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Martin B. Brenner CEO | NASDAQ (CM) Exchange | 451033203 CUSIP |
| US Country | 16 Employees | - Last Dividend | 29 Nov 2023 Last Split | - IPO Date |
Overview
iBio, Inc. is positioned at the forefront of biotechnological innovation by leveraging artificial intelligence (AI) to pioneer the development of next-generation biopharmaceuticals. The company's specialization in computational biology and 3D modeling of subdominant and conformational epitopes paves the way for the discovery of novel antibody treatments, particularly focusing on challenging cancer targets and other diseases. Since its incorporation in 2008 and based in San Diego, California, iBio, Inc. endeavors to transition vaccines and therapeutics from preclinical stages into groundbreaking medical solutions. With EngageTx™ and ShieldTx™ technologies under its belt, iBio is striving to redefine therapeutic and vaccine discovery and delivery, promising a future where treatment is not only more effective but also safer for patients.
Products and Services
- EngageTx™ Technology
- ShieldTx™ Technology
At the heart of iBio’s innovation, the EngageTx™ technology stands out for its focus on bi-specific molecules. This platform distinguishes itself by generating multiple hits, hence creating a vast sequence diversity. It is particularly notable for promoting Human-Cyno cross-reactivity, which is crucial for ensuring the efficacy of treatments across different species during the preclinical testing phase. Furthermore, EngageTx™ is designed to mitigate cytokine release, a common concern in the development of therapies, thus enhancing the safety profile of prospective treatments.
ShieldTx™ emerges as iBio's answer to the critical challenge of targeted antibody delivery. This patent-pending antibody masking technology is engineered with precision to ensure that therapeutic antibodies reach only diseased tissues, sparing the healthy ones from potential damage. This revolutionary approach not only maximizes the efficacy of treatments but also significantly minimizes side effects, offering a beacon of hope for patients with conditions that require highly targeted therapeutic interventions.
Contact Information
